Cyclodextrin-based polyrotaxanes and protein hybrids as three-dimensional printing inks

Today's cyclodextrin,

today’s cyclodextrin:
we have already talked about both rotaxanes and CD-supported 3D printing Now Dartmouth College, an invention form Chenfeng Ke; Qianming Lin; Miao Tang and Li Longyu presents the combination of the two.
Rotaxanes have numerous applications, including applications in three-dimensional printing. However, current rotaxanes have numerous limitations in terms of fabrication and properties optimal for 3D printing. For instance, the synthesis of cyclodextrin-based three-dimensional (3D)—printable polypseudorotaxanes, which are formed by threading α-cyclodextrins (α-CDs) onto linear polyethylene glycol (PEG), requires the use of high molecular weight PEG with a minimal molecular weight of 10 k Pa.
Rotaxanes presented in this patent overcome such handicaps and offer a feasible solution.

See the full patent here on Espacenet

Lipid-based RNA formulations suitable for therapy

Today's cyclodextrin, , , ,

today’s cyclodextrin:
In this invention, BioNTech SE provides a method of producing a composition comprising RNA lipoplex particles. The main focus of the description is antitumoral therapy.
In the formulation itself, the aqueous colloidal suspension of liposomes is combined with an aqueous solution comprising RNA, thereby producing the composition comprising RNA lipoplex particles. The formulation requires frozen storage conditions; hence the use of cyroprotectant is necessary. The invention proposes mono- di- and oligosaccharides to protect such compositions, including various cyclodextrins and cyclodextrin polymers.
The use of cyclodextrins as cryoprotectants and stabilizers in biopharmaceutical formulations is an emerging technology.

Dr. Hossam Hefesha, Heinrich Haas, Ferdia Bates, Christian Hotz
Katalin Karikó

See the full patent Patentscope

Polysaccharide-based nanogels for biomedical applications: A comprehensive review

carbohydrates, drug delivery,

The biomedical, biotech, and food industries all use polysaccharides as vital biomolecules with a variety of applications. Polysaccharides have great potential as biomaterials, and polysaccharide-based nanogels have attracted a lot of attention as carriers for different bioactive agents due to their unique versatile groups, specifically for site-directed or controlled delivery of the payload and, particularly because of their physicochemical properties, biodegradability, and biocompatibility. The 3D polymer network of NG produced by chemical crosslinking or physical self-assembly may be used to incorporate hydrophilic or hydrophobic molecules, including tiny drugs and proteins, genetic material patterns, and even ultrasmall nanoparticles. In this review, the chemistry of specific common polysaccharides and the various methods used to fabricate polysaccharide-based NG is discussed, with an emphasis on their use NG as drug delivery systems.

FOUAD DAMIRI, Dr.Satish Rojekar, Yahya Bachra, Rajender Varma, Dr. Swetha Andra, Satheesh kumar Balu, Dr. Chandrakantsing Pardeshi, Vijaysing Pardeshi, Hitendra Patel, Ana Cláudia Paiva-Santos, Mohammed Berrada, Mónica Cristina García

See the full article here

Three-in-one: exploration of co-encapsulation of cabazitaxel, bicalutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers

drug delivery, ,

Another great paper comes out of the long-term collaboration between our CSO,Milo Malanga and Ilse Manet‘s lab at National Research Council of Italy.
We explored a series of cyclodextrin (CyD) polymers composed either of a single CyD type or a mixture of two CyD types to encapsulate simultaneously different compounds with potential therapeutic interest for multimodal prostate cancer treatment. Thanks to a single inexpensive CyD-based polymer, we produced a three-in-one platform for the future implementation of combined chemotherapy and photodynamic therapy. These achievements are most relevant as nanomedicines are continuously proposed, but their potential for translation to the pharma industry is compromised by their limited potential for industrial upscale.

Elisabetta Pancani, PharmD, Marco Agnes, Arianna Mazza, Alessandro Venturini et al.

See the full article here

Treatment of cancer

carbohydrates, , , ,

This patent on CRLX-101, an experimental approach using camptothecin (CPT) to cancer chemotherapy, reminded us of a wonderful idea from Mark Davis (Caltech). In CRLX101, CPT is linked covalently through a glycine link to the linear copolymer CDP, which in turn consists of alternating subunits of beta-cyclodextrin and polyethylene glycol (PEG). The CRLX101 nanoparticle is water-soluble. After intravenous injection, active CPT is slowly released as the linkage is hydrolyzed. The size of the nanoparticle (20-50 nm in diameter) facilitates its extravasation in the more leaky vessels of tumors via the enhanced permeability and retention effect. As a result, the anticancer drug is enhanced and retained in the tumor tissue.
The new patent from Ellipses Pharma proposes novel applications dominantly in rectal cancer.
Amato Giaccia, Hanna Sanoff, Joel Tepper

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs

drug delivery, ,

As fellow stakeholders in developing novel drug delivery in gene therapy, we greatly admire the review of Sean Dilliard and Daniel Siegwart from The University of Texas Southwestern Medical School describing passive, active and endogenous organ-targeted lipid and polymer nanoparticles. Amazing compilation!

See the full article here